Circulatory disease accounts for fifteen million deaths each year, of which stroke accounts
for four and a half million-with an estimated nine million stroke survivors annually. The …

There is considerable interindividual variability in the response to antiplatelet and
anticoagulant therapies, and this variation may be attributable to genetic variants. There has …

Stroke is the fourth leading cause of mortality and neurological disability. It is caused by an
intricate interplay of environmental and genetic factors. Genes not only influence …

Stroke is the third cause of mortality and one of most frequent causes of long‐term
neurological disability, as well as a complex disease that results from the interaction of …

Epidemiologic evidence supports a genetic predisposition to stroke. Recent advances,
primarily using the genome-wide association study approach, are transforming what we …

Recombinant tissue-plasminogen activator (rtPA) is the only drug used during the acute
phase of stroke. Despite its important benefits, a percentage of patients suffer symptomatic …

Stroke remains a leading cause of death worldwide and the first cause of disability in the
western world. Ischemic stroke (IS) accounts for almost 80% of the total cases of strokes and …

Genetic variations have been shown to influence drug metabolism, risk of adverse drug
events, and pharmacodynamic responses for many drugs routinely used to treat patients …

Antiplatelet drugs are widely utilized in the setting of primary stroke prevention, secondary
stroke prevention, and neuroendovascular device-related stroke prevention. These …

Our knowledge of the pharmacogenetics of warfarin and clopidogrel continues to expand as
we learn more about the individual genetic variations that contribute to the drugs' efficacy …